RANI

Rani Therapeutics Holdings Stock Analysis

AI Rating

Neutral
  • Quality6/10
  • Growth↑ 5/10
  • Momentum↑ 7/10
Rani Therapeutics Holdings sales and earnings growth
RANI Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 25.47%
  • FCF Y/Y↑ 30.06%
Rani Therapeutics Holdings gross and profit margin trends
RANI Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -2359.60%
  • ROIC↓ -132.60%
Rani Therapeutics Holdings net debt vs free cash flow
RANI Risk
Great
  • Debt / Equity↓ -1.5
  • Debt / FCF↓ 0.5
  • Interest coverage↓ -6.7

Rani Therapeutics Holdings stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗